These findings may reflect the complexity of immune modulation in AD as dupilumab ameliorates IL‐4 and IL‐13 signaling but may not fully interfere with other biomarkers of Th2 activity, especially those related to B cell or Fc receptor pathways. This evidence concerns the gene IL13 and Alzheimer disease.